NT-proBNP level before primary PCI and risk of poor myocardial reperfusion: Insight from the On-TIME II trial

Am Heart J. 2021 Mar:233:78-85. doi: 10.1016/j.ahj.2020.12.017. Epub 2020 Dec 31.

Abstract

Background: N-terminal fragment of the brain natriuretic peptide prohormone (NT-proBNP), a marker for neurohumoral activation, has been associated with adverse outcome in patients with myocardial infarction. NT-proBNP levels may reflect extensive ischemia and microvascular damage, therefore we investigated the potential association between baseline NT-proBNP level and ST-resolution (STR), a marker of myocardial reperfusion, after primary percutaneous coronary intervention (pPCI).

Methods: we performed a post-hoc analysis of the On-TIME II trial (which randomized ST-elevation myocardial infarction (STEMI) patients to pre-hospital tirofiban administration vs placebo). Patients with measured NT-proBNP before angiography were included. Multivariate logistic-regression analyses was performed to investigate the association between baseline NTproBNP level and STR one hour after pPCI.

Results: Out of 984 STEMI patients, 918 (93.3%) had NT-proBNP values at baseline. Patients with STR <70% had higher NT-proBNP values compared to patients with complete STR (>70%) [Mean ±SD 375.2 ±1021.7 vs 1007.4 ±2842.3, Median (IQR) 111.7 (58.4-280.0) vs 168.0 (62.3-601.3), P <.001]. At multivariate logistic regression analysis, independent predictors associated with higher risk of poor myocardial reperfusion (STR <70%) were: NT-proBNP (OR 1.17, 95%CI 1.04-1.31, P = .009), diabetes mellitus (OR 1.87, 95%CI 1.14-3.07, P = .013), anterior infarct location (OR 2.74, 95% CI 2.00-3.77, P <.001), time to intervention (OR 1.06, 95%CI 1.01-1.11, P = .021), randomisation to placebo (OR 1.45, 95%CI 1.05-1.99, P = .022).

Conclusions: In STEMI patients, higher baseline NT-proBNP level was independently associate with higher risk of poor myocardial reperfusion, supporting the potential use of NT-proBNP as an early marker for risk stratification of myocardial reperfusion after pPCI in STEMI patients.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anterior Wall Myocardial Infarction / blood
  • Anterior Wall Myocardial Infarction / pathology
  • Biomarkers / blood*
  • Diabetes Mellitus / blood
  • Double-Blind Method
  • Female
  • Fibrinolytic Agents / administration & dosage
  • Humans
  • Male
  • Middle Aged
  • Myocardial Reperfusion*
  • Natriuretic Peptide, Brain / blood*
  • Peptide Fragments / blood*
  • Percutaneous Coronary Intervention
  • Prospective Studies
  • Regression Analysis
  • ST Elevation Myocardial Infarction / blood*
  • ST Elevation Myocardial Infarction / therapy
  • Time-to-Treatment
  • Tirofiban / administration & dosage
  • Young Adult

Substances

  • Biomarkers
  • Fibrinolytic Agents
  • Peptide Fragments
  • pro-brain natriuretic peptide (1-76)
  • Natriuretic Peptide, Brain
  • Tirofiban